Current Status of Bone-Forming Therapies for the Management of Osteoporosis

Autor: Bente L. Langdahl, Anne Sophie Koldkjær Sølling, Torben Harsløf
Rok vydání: 2019
Předmět:
Oncology
medicine.medical_treatment
Abaloparatide
Osteoporosis
0302 clinical medicine
Bone Density
Osteogenesis
Teriparatide
Teriparatide/therapeutic use
Pharmacology (medical)
030212 general & internal medicine
ALENDRONATE
Randomized Controlled Trials as Topic
Bone mineral
Bone Density Conservation Agents
Diphosphonates
Antibodies
Monoclonal
Bone Resorption/drug therapy
Osteogenesis/drug effects
Denosumab
POSTMENOPAUSAL WOMEN
ZOLEDRONIC ACID
TYPE-1 RECEPTOR
TERIPARATIDE RHPTH(1-34)
Drug Therapy
Combination
BISPHOSPHONATE-RELATED OSTEONECROSIS
Diphosphonates/therapeutic use
Osteoporosis/drug therapy
medicine.drug
PARATHYROID-HORMONE 1-34
medicine.medical_specialty
Bone Density Conservation Agents/therapeutic use
VERTEBRAL FRACTURES
Combination therapy
Antibodies
Monoclonal/therapeutic use
Denosumab/therapeutic use
03 medical and health sciences
Pharmacotherapy
Internal medicine
medicine
Humans
Bone Resorption
business.industry
Parathyroid Hormone-Related Protein
Bone Density/drug effects
Bisphosphonate
medicine.disease
ANTIRESORPTIVE THERAPY
Clinical trial
Clinical Trials
Phase III as Topic
MINERAL DENSITY
Parathyroid Hormone-Related Protein/therapeutic use
Geriatrics and Gerontology
business
030217 neurology & neurosurgery
Zdroj: Sølling, A S K, Harsløf, T & Langdahl, B 2019, ' Current Status of Bone-Forming Therapies for the Management of Osteoporosis ', Drugs & Aging, vol. 36, no. 7, pp. 625-638 . https://doi.org/10.1007/s40266-019-00675-8
ISSN: 1179-1969
DOI: 10.1007/s40266-019-00675-8
Popis: In patients with osteoporosis and severely reduced bone mass and/or recurring fractures, antiresorptive therapy may not be the optimal first-line treatment. Two recent clinical trials comparing bone-forming treatment with antiresorptive therapy have demonstrated that bone-forming treatment is superior in reducing the fracture risk in patients with severe osteoporosis. All of the currently available bone-forming agents-teriparatide, abaloparatide, and romosozumab-increase bone mineral density (BMD) and reduce the fracture risk; however, the effect wears off with time and treatment is therefore only transient. Thus, a bone-forming therapy should be followed by antiresorptive treatment with a bisphosphonate or denosumab. The BMD response to bone-forming treatment is reduced in patients previously treated with antiresorptive drugs; however, based on the findings of the VERO trial, the anti-fracture efficacy of bone-forming treatment in comparison with antiresorptives seems to be preserved. This review provides an overview of the existing bone-forming therapies for osteoporosis including considerations of sequential and combination therapy.
Databáze: OpenAIRE
Externí odkaz: